Dr. Shah Discusses Sequencing for MCL
Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses the sequencing of agents for patients with mantle cell lymphoma (MCL).
Sequencing will play a role in determining which treatments to give to patients with MCL. According to Shah, clinically, a patient with a p53 mutation should first receive lenalidomide (Revlimid).
The next big biomarker will be the ColonoSEQTM minimal residual disease (MRD) approach to assess death of remission, explains Shah.